Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113

男男性行为者停用富马酸替诺福韦酯/恩曲他滨进行暴露前预防后骨量的变化：青少年试验网络方案 110 和 113 的扩展阶段结果

阅读：1
作者：Havens,Peter L,Perumean-Chaney,Suzanne E,Patki,Amit,Cofield,Stacey S,Wilson,Craig M,Liu,Nancy,Anderson,Peter L,Landovitz,Raphael J,Kapogiannis,Bill G,Hosek,Sybil G,Mulligan,Kathleen
期刊：Clinical Infectious Diseases影响因子：7.300
时间：2020起止号：2020 Feb 3;70(4):687-691
doi：10.1093/cid/ciz486

Abstract

Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15-19 years. Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。